Welcome to our dedicated page for Novabay Pharma news (Ticker: NBY), a resource for investors and traders seeking the latest updates and insights on Novabay Pharma stock.
NovaBay Pharmaceuticals (NBY) delivers innovative non-antibiotic anti-infectives for ophthalmic care, wound management, and dermatological conditions. This page provides investors and healthcare professionals with timely updates on the company’s scientific advancements, regulatory milestones, and market strategies.
Access consolidated news about NBY’s Neutrox™ product line, including Avenova for chronic eye conditions, and developments in its Aganocide® compound research. Stay informed about financial disclosures, partnership announcements, and clinical trial outcomes through verified press releases and analysis.
Key updates include FDA submissions, international distribution expansions, and peer-reviewed study results. Our repository ensures efficient tracking of NovaBay’s progress in addressing antibiotic resistance challenges through its patented antimicrobial technologies.
Bookmark this page for direct access to NBY’s latest corporate communications. Check regularly for insights into commercialization efforts and research breakthroughs shaping the future of non-antibiotic therapies.
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announced that CEO Justin Hall will present a company overview at the virtual Sequire Biotechnology Conference on February 2 at 2:30 p.m. Eastern time. Avenova® unit sales achieved substantial growth in Q4 2022, indicating a positive trajectory for the company. In 2023, NovaBay plans to focus on its effective wound care products, anticipating significant contributions to revenue. An archived presentation will be accessible on the NovaBay website. Additionally, the company will report its 2022 financial results on March 23, 2023.
NovaBay Pharmaceuticals (NYSE American: NBY) announced an expansion of its commercial program for PhaseOne Skin and Wound Care Cleanser through partnerships with leading wound dressing manufacturers. The CEO, Justin Hall, emphasized expectations for wound care growth in 2023. The Managing Director of PhaseOne Health, Kris Perkins, highlighted past triple-digit growth and plans for synergistic business development in wound and surgical care. Notably, PhaseOne's formulation of hypochlorous acid has shown effectiveness in managing biofilm and promoting healing. The company is positioning itself for significant market opportunities in both wound care and other surgical applications.
NovaBay Pharmaceuticals (NBY) reported significant growth in its DERMAdoctor brand, driven by a successful marketing campaign on Douyin during China's Double 11 shopping festival. Sales increased by 26%, with online visitors rising by 258%. The company is expanding its presence in China, leveraging new partnerships and influencer marketing to tap into the world's largest e-commerce market. CEO Justin Hall noted that the campaign resulted in 15,000 new followers and over 30,000 orders on Tmall. NovaBay also continues to promote Avenova products through TikTok in the U.S., enhancing brand awareness.
NovaBay Pharmaceuticals announced the feature of its product, Calm Cool + Corrected Eczema + Dermatitis Clinical Repair Balm, on QVC's 'Give Gorgeous - Gifts With Purchase' on
NovaBay Pharmaceuticals reported a 69% revenue growth in Q3 2022, driven by robust DERMAdoctor product sales and increased demand for Avenova Spray units. The total net product revenue reached $3.8 million, with significant contributions from various product lines. Despite growth, gross margin dropped to 62% due to a higher mix of lower-margin products. The net loss for the quarter was $5.8 million, reflecting increased expenses linked to the acquisition and warrant adjustments. The company ended Q3 with $3.9 million in cash and plans to expand DERMAdoctor sales internationally.
NovaBay Pharmaceuticals (NYSE American: NBY) announced the approval of a 1-for-35 reverse stock split following stockholder approval on November 10, 2022. The split will take effect on November 15, 2022, at 4:15 p.m. ET, with trading on a split-adjusted basis commencing on November 16, 2022. This move aims to enhance the stock's marketability and liquidity, potentially aiding compliance with NYSE American listing requirements. The split will reduce outstanding shares from approximately 64 million to about 1.86 million while maintaining authorized shares and par values.
NovaBay Pharmaceuticals (NYSE American: NBY) will report its financial results for Q3 and YTD September 30, 2022, on
NovaBay Pharmaceuticals has launched its new 15% Niacinamide Pore Minimizing Serum as part of the DERMAdoctor Picture Porefect collection. This serum is designed to reduce the appearance of enlarged facial pores while providing antioxidant benefits and supporting collagen production. The formulation includes niacinamide, vitamin C, zinc, and peptides, targeting skin conditions like blackheads and discoloration. The product is priced at $42 and is available on Amazon and DERMAdoctor.
NovaBay Pharmaceuticals (NYSE American: NBY) will present a company overview at the LD Micro Main Event XV on October 26 at 8:00 a.m. Pacific time in Los Angeles. The event will showcase the company’s scientifically formulated eyecare and skincare products, including the Avenova lid and lash spray and DERMAdoctor skincare line. A live and archived webcast of the presentation will be accessible on the company's Events page.
NovaBay Pharmaceuticals (NBY) has announced substantial orders for its popular DERMAdoctor Kakadu C 20% Vitamin C Serum, especially timed for the holiday season. CEO Justin Hall indicated these orders are expected to boost revenue for the third and fourth quarters of 2022. The serum, containing stabilized vitamin C sourced from Kakadu plums in Australia, is recognized for its skin-brightening properties. DERMAdoctor products are sold through major retailers and online platforms, enhancing the company's market reach and potential growth.
